Amerithrax — Part 27

108 pages · May 08, 2026 · Document date: May 24, 2005 · Broad topic: Terrorism · Topic: Amerithrax · 102 pages OCR'd

‹

United States Patent: 6,387,665 r @ Page 2 of 11 * 5081029 Jan., 1992 Zarling et al. Other References Ivins et al. European J. Epidemiology. Mar. 1988. 4(1): 12-19* Ivins et al. Clin. Immunology Newsletter. 9(2): 30-32, 1988.* Uptake of Congo red by Virulent Strains of Bacillus Anthracis, Worsham et al., 1991 ASM Abstracts, p. 75. Understanding Biotechnology Law, edited by Gale R. Peterson, Marcel Dekker, Inc., (date unknown). Vaccine Efficacy of Bacillus anthracis Protective Antigen Produced in Pokaryotic and Eukaryotic Cells, Ivins, et al., Inst. Infect. Dis., Ft. Detric Frederick, MD, May 25, 1994. Immunization Against Anthrax with Aromatic Compound Dependent (Aro-) Mutants of Bacillus anthracis and with Recombinant Strains of Bacillus subtilis that Produce Anthrax Protective Antigen; Ivins, et al., Infect. and Immunity, Nov. 1986, vol. 54, No. 2, pp. 537- 542. Cloning and Expression of teh Bacillus anthracis, Ivins, et al.; Infect and Immunity, May 1986, vol. 52, No. 2, pp. 454-458. Expression of the Bacillus antracis Protective Antigen Gene by Baculovirus and Vaccinia Virus Recombinants; Icono-Connors, et al., Infect. and Immunity, Feb. 1990, vol. 58, No. 2, pp. 366-372. Protection against Anthrax with Recombinant Virus-Expressed Protective Antigen in Experimental Animals; Iacono-Connors, et al., Infect. and Immunity, Jun. 1991, vol. 59, No. 6, pp. 1961-1965. Primary Examiner: Graser; Jennifer E. Attorney, Agent or Firm: Arwine; Elizabeth, Moran; John Francis, Harris; Charles H. Parent Case Text This application is a divisional application of Ser. No. 08/346,238 filed Nov. 23, 1994, said application allowed. Claims What is claimed is: 1. A method of making a vaccine comprising: incorporating a protective antigen produced by recombinant asporogenic B. anthracis with a pharmaceutically acceptable carrier, wherein said recombinant asporogenic B. anthracis was isolated from a .DELTA.Sterne-1(pPA102) strain of bacteria and said recombinant asporogenic B. anthracis does not have the ability to bind a dye when grown on Congo Red Agar. 2. The method of claim 1, wherein the recombinant asporogenic B. anthracis is B. Anthracis .DELTA.Sterne-1(pPA 102)CR4. http://patit.uspto.gov/netacgi/nph-Parser?Sectl=PTO2&Sect2=HITOFF &u=/netahtml/sear... 6/28/2005

›

United States Patent: 6,387,665 r @ Page 2 of 11

* 5081029 Jan., 1992 Zarling et al.

Other References

Ivins et al. European J. Epidemiology. Mar. 1988. 4(1): 12-19*

Ivins et al. Clin. Immunology Newsletter. 9(2): 30-32, 1988.*

Uptake of Congo red by Virulent Strains of Bacillus Anthracis, Worsham et al., 1991 ASM
Abstracts, p. 75.

Understanding Biotechnology Law, edited by Gale R. Peterson, Marcel Dekker, Inc., (date
unknown).

Vaccine Efficacy of Bacillus anthracis Protective Antigen Produced in Pokaryotic and
Eukaryotic Cells, Ivins, et al., Inst. Infect. Dis., Ft. Detric Frederick, MD, May 25, 1994.
Immunization Against Anthrax with Aromatic Compound Dependent (Aro-) Mutants of
Bacillus anthracis and with Recombinant Strains of Bacillus subtilis that Produce Anthrax
Protective Antigen; Ivins, et al., Infect. and Immunity, Nov. 1986, vol. 54, No. 2, pp. 537-
542.

Cloning and Expression of teh Bacillus anthracis, Ivins, et al.; Infect and Immunity, May
1986, vol. 52, No. 2, pp. 454-458.

Expression of the Bacillus antracis Protective Antigen Gene by Baculovirus and Vaccinia
Virus Recombinants; Icono-Connors, et al., Infect. and Immunity, Feb. 1990, vol. 58, No. 2,
pp. 366-372.

Protection against Anthrax with Recombinant Virus-Expressed Protective Antigen in
Experimental Animals; Iacono-Connors, et al., Infect. and Immunity, Jun. 1991, vol. 59, No.
6, pp. 1961-1965.

Primary Examiner: Graser; Jennifer E.
Attorney, Agent or Firm: Arwine; Elizabeth, Moran; John Francis, Harris; Charles H.

Parent Case Text

This application is a divisional application of Ser. No. 08/346,238 filed Nov. 23, 1994, said application
allowed.

Claims

What is claimed is:

1. A method of making a vaccine comprising: incorporating a protective antigen produced by
recombinant asporogenic B. anthracis with a pharmaceutically acceptable carrier, wherein said
recombinant asporogenic B. anthracis was isolated from a .DELTA.Sterne-1(pPA102) strain of bacteria
and said recombinant asporogenic B. anthracis does not have the ability to bind a dye when grown on
Congo Red Agar.

2. The method of claim 1, wherein the recombinant asporogenic B. anthracis is B.
Anthracis .DELTA.Sterne-1(pPA 102)CR4.

http://patit.uspto.gov/netacgi/nph-Parser?Sectl=PTO2&Sect2=HITOFF &u=/netahtml/sear... 6/28/2005